3.04 Listener Questions & MedTwitter and Risk-Benefit Profile of Ramucirumab with Dr. Bishal Gyawali

from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH

This week we respond to several questions sent in by listeners and then we interview Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada on MedTwitter, other recent events, and his recently published paper titled "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials". Ramucirumab: doi.org/10.1016/j.eclinm.2020.100458 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Episode metadata supplied by the publisher feed · Published Jul 24, 2020

Embed this episode

Attribution link and audio player

Ready to play

3.04 Listener Questions & MedTwitter and Risk-Benefit Profile of Ramucirumab with Dr. Bishal Gyawali

0:00 1:31:46

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 1 hour and 31 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on July 24, 2020.

Can I download this Plenary Session - inactive due to federal service episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!